Novartis will close its Wehr production site in Germany by the end of 2028
Approximately 220 jobs will be eliminated in Germany due to the closure
The Wehr site manufactures tablets and capsules and is no longer competitive
The closure is not related to U.S. tariff threats or Germany's new healthcare measures
Novartis remains committed to Germany and states patient supply will not be disrupted
Novartis is investing €35 million in a new radioligand therapy production facility in Halle, Saxony-Anhalt, expected to become operational in 2027
Novartis employs over 2,600 people across six sites in Germany